Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Scented candles as an unrecognised factor that increases the risk of bladder cancer; is there enough evidence to raise a red flag?

Adamowicz J, Juszczak K, Poletajew S, van Breda SV, Pokrywczynska M, Drewa T.

Cancer Prev Res (Phila). 2019 Aug 9. pii: canprevres.0093.2019. doi: 10.1158/1940-6207.CAPR-19-0093. [Epub ahead of print]

PMID:
31399420
2.

The 1973 WHO and 2004 WHO grading systems are not equal in prediction of survival among stage T1 bladder cancer patients.

Krajewski W, Rodríguez-Faba O, Breda A, Pisano F, Poletajew S, Tukiendorf A, Algaba F, Zdrojowy R, Kołodziej A, Palou J.

Actas Urol Esp. 2019 Jul 2. pii: S0210-4806(19)30100-7. doi: 10.1016/j.acuro.2019.03.011. [Epub ahead of print] English, Spanish.

PMID:
31272800
3.

Validation of the CUETO scoring model for predicting recurrence and progression in T1G3 urothelial carcinoma of the bladder.

Krajewski W, Rodríguez-Faba O, Breda A, Pisano F, Poletajew S, Tukiendorf A, Zdrojowy R, Kołodziej A, Palou J.

Actas Urol Esp. 2019 May 30. pii: S0210-4806(19)30066-X. doi: 10.1016/j.acuro.2019.02.006. [Epub ahead of print] English, Spanish.

PMID:
31155372
4.

The TaHG bladder cancer - the devil is as black as he is painted.

Krajewski W, Poletajew S.

Cent European J Urol. 2019;72(1):76-77. doi: 10.5173/ceju.2018.1873. Epub 2019 Feb 15. No abstract available.

5.

Surgical treatment for renal masses in the elderly: analysis of oncological, surgical and functional outcomes.

Poletajew S, Zapała P, Kopczyński B, Białek L, Bender S, Mutrynowski T, Nowak M, Mróz J, Pędzisz G, Dybowski B, Radziszewski P.

Int Braz J Urol. 2019 May-Jun;45(3):531-540. doi: 10.1590/S1677-5538.IBJU.2018.0310.

6.

A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical bacillus Calmette-Guérin immunotherapy.

Poletajew S, Krajewski W, Adamowicz J, Radziszewski P.

Anticancer Drugs. 2019 Jun;30(5):517-522. doi: 10.1097/CAD.0000000000000775.

PMID:
30870228
7.

Expression of E-cadherin, β-catenin, and epithelial membrane antigen does not predict survival in patients with high-risk non-muscle-invasive bladder cancer.

Poletajew S, Fus Ł, Ilczuk T, Wojcieszak P, Sękowska M, Krajewski W, Wasiutyński A, Górnicka B, Radziszewski P.

Cent Eur J Immunol. 2018;43(4):421-427. doi: 10.5114/ceji.2018.79509. Epub 2018 Dec 31.

8.

New predictive nomograms for non-muscle-invasive bladder cancer: it is all about the details.

Krajewski W, Rodríguez Faba O, Poletajew S, Palou J.

World J Urol. 2019 Feb 18. doi: 10.1007/s00345-019-02680-3. [Epub ahead of print] No abstract available.

PMID:
30778671
10.

Bimanual palpation for staging of bladder cancer-clinical use and its predictors.

Bialek L, Poletajew S, Magusiak PM, Ostrach M, Szpernalowski J, Dybowski B, Radziszewski P.

Turk J Urol. 2018 Nov 21;45(1):22-26. doi: 10.5152/tud.2018.27243.

11.

Catheter-associated bacterial flora in patients with benign prostatic hyperplasia: shift in antimicrobial susceptibility pattern.

Dybowski BA, Zapała P, Bres-Niewada E, Zapała Ł, Miązek-Zapała N, Poletajew S, Młynarczyk G, Radziszewski P.

BMC Infect Dis. 2018 Nov 20;18(1):590. doi: 10.1186/s12879-018-3507-9.

12.

The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.

Krajewski W, Zdrojowy R, Dembowski J, Poletajew S, Wróbel M, Łuczak M, Tukiendorf A, Kolodziej A.

Urol Int. 2019;102(1):60-68. doi: 10.1159/000491642. Epub 2018 Sep 28.

PMID:
30269132
13.

Influence of Transurethral Resection of Bladder Cancer on Sexual Function, Anxiety, and Depression.

Krajewski W, Halska U, Poletajew S, Piszczek R, Bieżyński B, Matyjasek M, Tukiendorf A, Menzel F, Mazur M, Rymaszewska J, Zdrojowy R.

Adv Exp Med Biol. 2018;1116:37-50. doi: 10.1007/5584_2018_264.

PMID:
30242788
14.

Are There Differences in Toxicity and Efficacy between Various Bacillus Calmette-Guerin Strains in Bladder Cancer Patients? Analysis of 844 Patients.

Krajewski W, Matuszewski M, Poletajew S, Grzegrzółka J, Zdrojowy R, Kołodziej A.

Urol Int. 2018;101(3):277-284. doi: 10.1159/000492722. Epub 2018 Sep 18.

PMID:
30227437
15.

A stone pushed back to the collecting system - long therapeutic path in centers with limited access to flexible instruments.

Bres-Niewada E, Dybowski B, Zapała P, Poletajew S, Miązek-Zapała N, Michałek I, Radziszewski P.

Cent European J Urol. 2018;71(2):186-189. doi: 10.5173/ceju.2018.1716. Epub 2018 Jun 12.

16.

[Infectious complications of prostate biopsy].

Łykowski M, Dybowski B, Poletajew S, Piecha T, Radziszewski P.

Wiad Lek. 2018;71(2 pt 2):371-377. Review. Polish.

PMID:
29786588
17.

Immunohistochemical differentiation between muscularis mucosae and muscularis propria for improving the staging of bladder cancer in patients undergoing transurethral resection of bladder tumours.

Poletajew S, Wolińska E, Wasiutyński A, Dybowski B, Radziszewski P, Górnicka B.

Pol J Pathol. 2017;68(3):218-224. doi: 10.5114/pjp.2017.71529.

18.

Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer.

Zapała P, Dybowski B, Poletajew S, Białek Ł, Niewczas A, Radziszewski P.

World J Surg Oncol. 2018 Jan 15;16(1):6. doi: 10.1186/s12957-018-1310-0.

19.

Predictors and prognostic implications of clinical decisions in patients with primary high-risk non-muscle-invasive bladder cancer - results of a cross country retrospective study.

Poletajew S, Biernacki R, Buraczynski P, Chojnacki J, Czarniecki S, Gajewska D, Pohaba T, Sondka-Migdalska J, Skrzypczyk M, Suchojad T, Wojtkowiak D, Zaforemski B, Zapala L, Zemla A, Radziszewski P.

Neoplasma. 2018;65(1):147-152. doi: 10.4149/neo_2018_170217N123.

PMID:
29322799
20.

Factors affecting one-year survival after radical cystectomy: A prospective study.

Kwiatkowska M, Dybowski B, Kuczkiewicz-Siemion O, Osiecki R, Śmigielska K, Gonczar S, Poletajew S, Radziszewski P.

Cent European J Urol. 2017;70(3):238-244. doi: 10.5173/ceju.2017.1484. Epub 2017 Aug 8.

21.

Availability and Patterns of Intravesical BCG Instillations.

Poletajew SA, Majek A, Magusiak P, Ledzikowska K, Dybowski B, Radziszewski P.

Urol J. 2017 Nov 4;14(6):5068-5070. doi: 10.22037/uj.v14i6.3781.

22.

What Can Be Expected from Prostate Cancer Biomarkers A Clinical Perspective.

Zapała P, Dybowski B, Poletajew S, Radziszewski P.

Urol Int. 2018;100(1):1-12. doi: 10.1159/000479982. Epub 2017 Sep 15. Review.

23.
24.

Endoscopic appearance of a tumor can predict the stage of bladder cancer.

Poletajew S, Radziszewski P.

Cent European J Urol. 2017;70(1):27-28. doi: 10.5173/ceju.2017.1242. Epub 2017 Mar 14. No abstract available.

25.

Anaesthesia of the posterior urethra and pain reduction during cystoscopy - a randomized controlled trial.

Poletajew S, Bender S, Pudełko P, Łykowski M, Piecha T, Sutkowski B, Radziszewski P.

Wideochir Inne Tech Maloinwazyjne. 2017;12(1):75-80. doi: 10.5114/wiitm.2017.66506. Epub 2017 Mar 13.

26.

AUTHOR'S REPLY.

Poletajew S, Torz C, Radziszewski P.

Cent European J Urol. 2016;69(4):397. doi: 10.5173/ceju.2016.944. Epub 2016 Nov 30. No abstract available.

27.

A prospective, randomized trial comparing the use of KTP (GreenLight) laser versus electroresection-supplemented laser in the treatment of benign prostatic hyperplasia.

Torz C, Poletajew S, Radziszewski P.

Cent European J Urol. 2016;69(4):391-395. doi: 10.5173/ceju.2016.859. Epub 2016 Nov 30.

28.

Extent of lymphadenectomy in patients with bladder cancer undergoing radical cystectomy - a multi-institutional analysis.

Piotrowicz S, Poletajew S, Czarniecki SW, Kowalski F, Nowak G, Oszczudłowski M, Sochaj M, Dobruch J, Radziszewski P.

Cent European J Urol. 2016;69(4):323-326. doi: 10.5173/ceju.2016.902. Epub 2016 Oct 19.

29.

Patterns of care in patients with muscle-invasive bladder cancer - a retrospective cohort study.

Poletajew S, Biernacki R, Buraczyński P, Chojnacki J, Czarniecki S, Gajewska D, Pohaba T, Sondka J, Skrzypczyk M, Suchojad T, Wojtkowiak D, Zaforemski B, Zapała Ł, Zemła A, Radziszewski P; Residents Section of the Polish Urological Association.

Contemp Oncol (Pozn). 2016;20(4):341-3. doi: 10.5114/wo.2016.61857. Epub 2016 Sep 5.

31.

Stage of bladder cancer in Central Europe - Polish perspective.

Poletajew S, Biernacki R, Buraczynski P, Chojnacki J, Czarniecki S, Gajewska D, Pohaba T, Sondka J, Skrzypczyk M, Suchojad T, Wojtkowiak D, Zaforemski B, Zapala L, Zemla A, Radziszewski P.

Neoplasma. 2016;63(4):642-7. doi: 10.4149/neo_2016_420.

PMID:
27268930
32.

[Not Available].

Toutounchi S, Poletajew S, Krajewska E, Koperski Ł, Pogorzelski R.

Magy Seb. 2015 Oct;68(5):204-8. doi: 10.1556/1046.68.2015.5.3. Hungarian.

PMID:
26481074
33.

Timing of radical cystectomy in Central Europe - multicenter study on factors influencing the time from diagnosis to radical treatment of bladder cancer patients.

Poletajew S, Braticevici B, Brisuda A, Cauni V, Grygorenko V, Lesnyak MZ, Lisiński J, Persu C, Renk K, Radziszewski P.

Cent European J Urol. 2015;68(1):9-14. doi: 10.5173/ceju.2015.01.444. Epub 2014 Dec 17.

34.

Author'S reply.

Persu C, Poletajew S.

Cent European J Urol. 2015;68(1):17. doi: 10.5173/ceju.2015.01.r95. No abstract available.

35.

Antigenic profile of muscularis mucosae and muscularis propria of the urinary bladder.

Poletajew S, Wilczek E, Wasiutyński A, Górnicka B.

Iran J Immunol. 2015 Mar;12(1):50-63. doi: IJIv12i1A5.

36.

Comparison of pathological staging and grading of urothelial bladder carcinoma in post-transurethral resection and post-radical cystectomy specimens.

Poletajew S, Fus Ł, Walędziak M, Pomada P, Ciechańska J, Wasiutyński A, Radziszewski P, Górnicka B.

Pol J Pathol. 2014 Dec;65(4):305-12.

37.

The time from diagnosis of bladder cancer to radical cystectomy in Polish urological centres - results of CysTiming Poland study.

Poletajew S, Lisiński J, Moskal K, Ornat J, Renk K, Szlaga M, Tworkiewicz J, Wojtkowiak D, Wołyniec P, Woźniak K, Zapała Ł, Radziszewski P.

Cent European J Urol. 2014;67(4):329-32. doi: 10.5173/ceju.2014.04.art2. Epub 2014 Dec 5.

38.

The incidence of renal cancer in Polish National Cancer Registry: is there any epidemiological data we can rely on?

Wojcieszak PZ, Poletajew S, Rutkowski D, Radziszewski P.

Cent European J Urol. 2014;67(3):253-6. doi: 10.5173/ceju.2014.03.art8. Epub 2014 Aug 18.

39.

Interobserver variability of Clavien-Dindo scoring in urology.

Poletajew S, Zapała L, Piotrowicz S, Wołyniec P, Sochaj M, Buraczyński P, Lisiński J, Swiniarski P, Radziszewski P; Residents Section of Polish Urological Association.

Int J Urol. 2014 Dec;21(12):1274-8. doi: 10.1111/iju.12576. Epub 2014 Jul 15.

40.

Letter to the editor.

Poletajew S, Radziszewski P.

Cent European J Urol. 2014;67(1):116. doi: 10.5173/ceju.2014.01.art30. No abstract available.

41.

Editorial comment.

Poletajew S, Radziszewski P.

Cent European J Urol. 2013;66(1):20-1. doi: 10.5173/ceju.2013.01.art6. No abstract available.

42.

Spontaneous regression of renal cell carcinoma.

Janiszewska AD, Poletajew S, Wasiutyński A.

Contemp Oncol (Pozn). 2013;17(2):123-7. doi: 10.5114/wo.2013.34613. Epub 2013 Apr 29.

43.

Macroscopic hematuria-a leading urological problem in patients on anticoagulant therapy: is the common diagnostic standard still advisable?

Antoniewicz AA, Zapała L, Poletajew S, Borówka A.

ISRN Urol. 2012;2012:710734. doi: 10.5402/2012/710734. Epub 2012 Apr 1.

44.

Urothelial bladder carcinoma in young patients is characterized by a relatively good prognosis.

Poletajew S, Walędziak M, Fus Ł, Pomada P, Ciechańska J, Wasiutyński A.

Ups J Med Sci. 2012 Mar;117(1):47-51. doi: 10.3109/03009734.2011.650797. Epub 2012 Jan 30.

45.

Current concepts on pathogenesis and biology of metastatic osteosarcoma tumors.

Poletajew S, Fus L, Wasiutyński A.

Ortop Traumatol Rehabil. 2011 Nov-Dec;13(6):537-45. Review. English, Polish.

PMID:
22248458
46.

Samuel Goldflam (1852-1932) - promoter of modern neurology and his contribution to urology.

Poletajew S.

Cent European J Urol. 2012;65(3):113-5. doi: 10.5173/ceju.2012.03.art2. Epub 2012 Sep 4. Review.

47.

Blood loss during laparoscopic radical prostatectomy - is it significant or not?

Poletajew S, Antoniewicz AA.

Cent European J Urol. 2012;65(1):11-3. doi: 10.5173/ceju.2012.01.art3. Epub 2012 Mar 19.

48.

Lack of evidence for increased level of circulating urothelial cells in the peripheral blood after transurethral resection of bladder tumors.

Antoniewicz AA, Paziewska A, Mikula M, Goryca K, Dabrowska M, Poletajew S, Borowka A, Ostrowski J.

Int Urol Nephrol. 2012 Jun;44(3):761-7. doi: 10.1007/s11255-011-0102-z. Epub 2011 Dec 9.

49.

Renal function and adaptive changes in patients after radical or partial nephrectomy.

Antoniewicz AA, Poletajew S, Borówka A, Pasierski T, Rostek M, Pikto-Pietkiewicz W.

Int Urol Nephrol. 2012 Jun;44(3):745-51. doi: 10.1007/s11255-011-0058-z. Epub 2011 Sep 21.

50.

Kidney removal: the past, presence, and perspectives: a historical review.

Poletajew S, Antoniewicz AA, Borówka A.

Urol J. 2010 Fall;7(4):215-23. Review.

Supplemental Content

Loading ...
Support Center